Search Results
Your search for it matches 15746 pages
Showing 2001 - 2050Delaying Treatment for Patients With Localized Prostate Cancer May Not Increase Mortality Risk, ProtecT Trial Shows
Patients with prostate cancer who undergo active monitoring may experience the same 15-year survival rates as those who undergo radiotherapy or surgery, according to new findings published by Hamdy et al in The New England Journal of Medicine and simultaneously presented at the 2023 European...
Large Study Finds Digital Breast Tomosynthesis May Be Superior to Digital Mammography for Breast Cancer Detection
In a study of over a million patients, digital breast tomosynthesis (DBT) showed improved breast cancer screening outcomes over screening with standard digital mammography alone. The results were published by Conant et al in Radiology. Breast cancer screening with two-dimensional (2D) digital...
Health-Related Quality of Life in the KEYNOTE-826 Trial in Patients With Cervical Cancer
In an analysis from the phase III KEYNOTE-826 trial reported in The Lancet Oncology, Bradley J. Monk, MD, and colleagues found that the addition of pembrolizumab to chemotherapy with or without bevacizumab did not adversely affect health-related quality of life in patients with persistent,...
Novel Urine Test May Play a Role in Bladder Cancer Prediction
Testing for genetic mutations in urine may help clinicians detect bladder cancer years before the disease shows clinical symptoms, according to new findings presented by Le Calvez-Kelm et al at the 2023 European Association of Urology Annual Congress (Abstract A0268). The researchers identified...
New Technique May Reduce Postoperative Complications in Prostate Cancer Surgery
Researchers have found that a novel technique used during prostate cancer surgery may reduce the risk of postoperative lymphocele by 50%, according to new findings presented by Neuberger et al at the 2023 European Association of Urology Annual Congress (Abstract A0656). The technique—involving the...
Digital Rectal Examination Fails to Detect Early Prostate Cancer, Study Shows
A common method of detecting prostate cancer may not be accurate enough to serve as a reliable screening tool by itself, researchers have warned. The digital rectal exam (DRE), in which health-care providers check the prostate gland with a finger for unusual swelling or lumps in the rectum, is...
PSMA-PET/CT May Help Improve Clinical Treatment of Prostate Cancer
A trial conducted at the University Hospital Bonn, Germany, has been testing the benefit of PSMA-PET/CT (prostate-specific membrane antigen–positron-emission tomography/computed tomography) to help target where to take biopsy samples, potentially improving the diagnosis of prostate cancer by giving ...
Study Reveals New Understanding of How Androgen Therapy Affects Breast Tissue
Molecular changes observed in the breast tissue of transgender men undergoing androgen therapy may signal the potential for also using the hormone to prevent or treat estrogen receptor–positive breast cancer. The findings were published by Raths et al in Cell Genomics. “These findings build upon...
I’m Doing My Part to Erase the Stigma Surrounding Lung Cancer
Ironically, I received a diagnosis of lung cancer when I was feeling my healthiest. In December 2015, when I was just 51 years old, a routine chest x-ray found a small shadow on the lower lobe of my right lung. Despite being a never-smoker, a regular exerciser, and a healthy eater, my primary care...
'Don't Blame the Test'
“There are misconceptions about prostate cancer screening,” Karen Knudsen, MBA, PhD, said in an interview with The ASCO Post about newly published cancer statistics, including an increased incidence of prostate cancer, particularly advanced-stage disease. Dr. Knudsen is Chief Executive Officer of...
Cancer Mortality Decreased 33% in Newest Data Reported by the American Cancer Society
Overall cancer mortality rates have decreased 33% since 1991, and cervical cancer incidence decreased 65% from 2012 through 2019, according to the latest statistics reported by the American Cancer Society (ACS).1 Amid this good news, however, was a troubling 3% annual increase in prostate cancer...
Tucatinib With Trastuzumab in Previously Treated RAS Wild-Type HER2-Positive Advanced Colorectal Cancer
On January 19, 2023, tucatinib was grated accelerated approval for use in combination with trastuzumab for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer that progressed following fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.1 Supporting Efficacy...
Unique Challenges of Cancer Care in India
In this installment of The ASCO Post’s Global Oncology, guest editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, spoke with Rajendra Toprani, MBBS, MS, MCh, Head of the Department of Head and Neck Surgical Oncology at HCG Cancer Centre, Ahmedabad, India. Dr. Toprani’s areas of interest include oral,...
First ASCO Guideline for Immunotherapy and Targeted Therapy in Advanced Gastroesophageal Cancer Now Available
An ASCO expert panel has developed a comprehensive guideline for immunotherapy and targeted therapy in patients with advanced gastroesophageal cancer.1 The guideline is based on the many recent advances in immunotherapy and targeted therapy. “The role of immunotherapy has changed practice in the...
Oncologists Applaud State of the Union’s Focus on Ending Cancer as We Know It
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO and the Association for Clinical Oncology, issued the following statement after President Joseph Biden’s State of the Union address on February 7. “ASCO applauds President Biden’s focus on ‘ending cancer as ...
Pilot Program Shows Diversity-Focused Clinical Trial Tools Are Useful at Cancer Research Sites
Cancer research sites demonstrated the utility of new resources designed to increase the diversity of participants in cancer clinical trials, although challenges remain, according to two studies published recently in JCO Oncology Practice.1,2 The studies examine the results from a collaborative...
Highlights of the 2022 Annual Conference of the International Society of Geriatric Oncology
The 2022 Annual Conference of the International Society of Geriatric Oncology (SIOG) was held in Geneva, Switzerland, on October 28–30, 2022. The meeting was held in conjunction with the SIOG 2022 Public Policy Meeting: Global Policy to Action on Cancer in the Aging Population at UN Headquarters...
Sacituzumab Govitecan-hziy in HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
On February 3, 2023, sacituzumab govitecan-hziy was approved for unresectable locally advanced or metastatic hormone receptor (HR)-positive, HER2-negative (immunohistochemistry [IHC] 0, IHC 1+, or IHC 2+/in situ hybridization–negative) breast cancer who have received endocrine-based therapy and at...
‘Best of SABCS’: Top 7 Picks From the 2022 Meeting by Jame Abraham, MD, FACP
Among the high-quality abstract presentations at the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. Each year, The ASCOPost asks our Associate Editor, breast cancer specialist Jame Abraham, MD, FACP, to give us his picks. Dr. Abraham is Chairman of ...
Radiation Oncology Workforce Expected to Remain Stable Through 2030, According to ASTRO Report
After analyzing the U.S. radiation oncology workforce, investigators projected a relative balance between the supply of radiation oncologists and the demand for radiation therapy services through 2030, according to an American Society for Radiation Oncology (ASTRO) Workforce Taskforce review...
Blood Test May Identify Patients With AML at Greater Risk of Relapse After Bone Marrow Transplant
Researchers have found that screening for residual disease prior to a bone marrow transplant may help physicians identify which adult patients in remission from acute myeloid leukemia (AML) are at risk of relapsing after the procedure, according to a novel study published by Dillon et al in JAMA....
Elacestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
On January 27, 2023, elacestrant was approved by the U.S. Food and Drug Administration (FDA) for postmenopausal women or adult men with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine ...
Phase III Trials Confirm Benefit of First-Line Anti–PD-1 Inhibition Plus Chemotherapy in Gastric Cancer
Two phase III trials evaluating the addition of drugs targeting PD-1 to chemotherapy—RATIONALE 305 and CheckMate 649—confirmed the benefit of this approach as first-line therapy for advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma, in findings presented at the 2023 ASCO GI...
Working Together to Close the Global Care Gap
The COVID-19 pandemic has underscored that public health is the product of one global, integrated ecosystem. Although it is tempting to focus on specific aspects of local health-care systems, or the political or physical environment, health and health care in other countries also impacts the United ...
Improving Physician-Patient Communication
In 2017, ASCO published a new guideline in the Journal of Clinical Oncology outlining the best practices for communicating effectively with patients and their family members.1 The goal of the communication guideline is to provide oncologists with a framework of specific practices to enable them to...
Understanding the Link Between Prognostic Perception and Patient-Oncologist Prognostic Discordance in the Advanced Cancer Setting
Studies have shown that although patients with advanced cancer want their oncologists to give them an honest assessment of their prognosis, most patients still perceive their illness as curable.1 And that lack of understanding of their prognosis can lead to reduced use of hospice care and increased ...
Expert Point of View: Elena Castro, MD, PhD
Formal discussant of the TRITON3 trial, Elena Castro, MD, PhD, of the Hospital Universitario 12 de Octubre, Madrid, noted that the study helps to answer several questions raised by the PROfound trial. In the PROfound trial, a cohort of patients with at least one alteration in BRCA1, BRCA2, or ATM...
TRITON3 Trial: Rucaparib Extends Progression-Free Survival in Selected Patients With Metastatic Castration-Resistant Prostate Cancer
The poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib prolonged imaging-based progression-free survival vs physician’s choice of therapy in patients with metastatic castration-resistant prostate cancer whose tumors harbored BRCA or ATM alterations. These results of the phase III TRITON3 study ...
Expert Point of View: Michiel S. Van der Heijden, MD, PhD
Formal discussant of the CheckMate 274 trial, Michiel S. Van der Heijden, MD, PhD, of the Netherlands Cancer Institute, said it is an “important” study. “In looking at these results, one should consider the goal of adjuvant therapy in this setting. Is overtreatment of patients cured by surgery...
Fewer Cases of Melanoma and Extracutaneous Malignancies Detected Among Patients With Atopic Diseases
Researchers have found that patients with a history of atopic diseases may be less likely to develop melanoma than patients with a history of nonatopic diseases, according to a new study published by Komulainen et al in Melanoma Research. The findings also revealed that patients with atopic...
Depression May Be Linked to Higher Levels of Inflammation, Poorer Outcomes in Patients With Lung Cancer
Patients with lung cancer who have moderate to severe depression may be two to three times more likely to have inflammation levels that predict poor survival rates, according to a new study published by Andersen et al in PLOS One. The findings may help explain why a substantial portion of patients...
Regardless of Income, American Indian/Native American Women May Be Less Likely to Undergo Mammography Than White Women
Investigators found that American Indian/Native American women living in higher-income communities did not have a higher mammography uptake compared with American Indian/Native American women living in lower-income communities, according to a new study published by Christensen et al in the American ...
Access to Paid Sick Leave May Result in More Cancer Screenings
More individuals may undergo cancer screenings when employers are mandated to provide paid sick leave, according to a new study published by Callison et al in The New England Journal of Medicine. Researchers found that breast cancer screening rates increased up to 4% and colorectal cancer...
Hormone Therapy May Reduce Risk of Lung Cancer in Female Patients, Despite Former Misperceptions
Investigators have demonstrated that, despite some commonly held misperceptions, hormone therapy doesn’t increase patients’ risk of developing lung cancer—and it could help reduce the risk, according to a 16-year population-based study published by Wu et al in Menopause. The findings may help...
Cancer Organizations Respond to Turkey and Syria Earthquakes
On February 6, 2023, a powerful 7.8-magnitude earthquake, followed by a second 7.5-magnitude quake, struck southeast Turkey and northwest Syria. To date, the quakes and several major aftershocks have killed nearly 52,000 citizens—more than 45,000 in Turkey and more than 6,700 in Syria—and injured...
Black Women at High Risk of Breast Cancer May Face Obstacles in Receiving Preventive Care
Black women at high risk of developing breast cancer may face a variety of obstacles keeping them from receiving preventive care that could increase their chances of survival if they did develop the disease, according to a new study published by Padamsee et al in PLOS One. The new findings provide...
Vitamin B5 May Help Improve Red Blood Cell Production in Patients With Myelodysplastic Syndromes
Researchers have discovered that vitamin B5 in combination with existing drugs may be the key to improving outcomes in patients with myelodysplastic syndromes (MDS) and ineffective red blood cell production, according to a novel study published by Mian et al in Science Translational Medicine....
How Patient Navigation Programs Are Helping Drive Equitable Care for Patients With Cancer and Improve Outcomes
Although patient navigation is increasingly recognized as an important component in the delivery of patient-centered cancer care, the service is not universally available across all cancer programs in the United States, often because of the concerns of extra cost without tangible financial...
American Cancer Society Data Show Colorectal Cancer Rates Are Rising in Younger Adults and Shifting to More Advanced Disease in People of All Ages
According to the American Cancer Society, colorectal cancer is the third most commonly diagnosed cancer and the third most common cause of cancer-related death in both men and women in the United States. However, it ranks second in cancer-related deaths overall, and is the leading cause of death in ...
Combination Chemotherapy May Be Safe and Effective Alternative for the Treatment of Patients With Non–Muscle-Invasive Bladder Cancer Amid BCG Shortage
Researchers have found that a safe, inexpensive chemotherapy combination may be better tolerated and more effective at preventing high-grade recurrence in patients with non–muscle-invasive bladder cancer than the standard-of-care bacillus Calmette-Guérin (BCG), according to a novel study published...
Combination Abatacept, Ruxolitinib, and/or Mechanical Ventilation May Decrease Mortality in Patients With Immune Checkpoint Inhibitor–Associated Cardiotoxicity
Although immune checkpoint inhibitors have substantially improved clinical outcomes in many cancer types, they have also been found to induce immune-related adverse events, including myocarditis, in about 1% of patients receiving the agents, which can lead to a mortality rate of up to 50%. Current...
Millions of U.S. Individuals May Have Missed Cancer Screenings During Second Year of COVID-19 Pandemic
Investigators have found that millions of individuals in the United States continued to miss critical cancer screening tests during the second year of the COVID-19 pandemic, according to a new study published by Star et al in the Journal of Clinical Oncology. Compared with 2019 levels, individuals...
Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
On January 19, 2023, the kinase inhibitor zanubrutinib was approved for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).1 Supporting Efficacy Data Approval was based on findings in the SEQUOIA trial (ClinicalTrials.gov identifier NCT03336333) in patients with...
ASCO Updates ‘Living’ Guidelines on Stage IV NSCLC Based on DESTINY-Lung01, CodeBreaK100, Other Trials
ASCO has updated its living guidelines for therapy for stage IV non–small cell lung cancer (NSCLC) with and without driver alterations based on newly available evidence in the field.1,2 “Living guidelines are becoming more important as the field of oncology expands and developments occur more...
ASCO Endorses CAP Guideline to Better Define Who Benefits From Immune Checkpoint Inhibitor Therapy
ASCO has endorsed a new guideline from the College of American Pathologists (CAP) on the use of mismatch repair (MMR) and microsatellite instability (MSI) testing, which could help oncologists more accurately identify patients who may be suitable candidates for immune checkpoint inhibitor ...
INTRIGUE Study: Circulating Tumor DNA Analysis May Predict Optimal Treatment of Patients With GIST
Circulating tumor DNA (ctDNA) analysis of KIT exon mutations may help to predict which second-line therapy is best for patients with advanced gastrointestinal stromal tumor (GIST), according to data presented during the ASCO Plenary Series: January 2023 Session.1 Exploratory analysis of the phase...
Expert Point of View: Pretesh R. Patel, MD
Session co-moderator, Pretesh R. Patel, MD, Associate Professor of Radiation Oncology at Winship Cancer Institute of Emory University, shared his thoughts on the Neo-AEGIS1 findings with The ASCO Post. “I think we continue to have equipoise about chemoradiation and perioperative chemotherapy in...
Neo-AEGIS Trial Finds Two Approaches Comparable in Treating Advanced Esophageal Cancer
A randomized trial that sought to determine the optimal approach to treating locally advanced esophageal or gastroesophageal junction cancer has ended in “equipoise,” according to the investigators of the Neo-AEGIS trial. In a study reported at the 2023 ASCO GI Cancers Symposium, perioperative...
Expert Point of View: Laura Goff, MD, MSCI
Invited discussant Laura Goff, MD, MSCI, Associate Professor of Medicine and Executive Medical Director for the Cancer Patient Care Center at Vanderbilt-Ingram Cancer Center, Nashville, said that with the results of NAPOLI-3, clinicians have a third effective first-line regimen for metastatic...
Have We Reached the Limits of Chemotherapy for Burkitt Lymphoma?
Burkitt lymphoma (BL) is a fascinating disease from which many groundbreaking medical and oncologic lessons have been learned. Since the Irish surgeon Denis P. Burkitt, MD, FRCS, FRS, first described rapidly enlarging jaw and facial tumors in Ugandan children in 1958,1 the study of BL has led to...
